Filing Details
- Accession Number:
- 0000899243-15-002970
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-08-12 17:06:49
- Reporting Period:
- 2015-08-10
- Filing Date:
- 2015-08-12
- Accepted Time:
- 2015-08-12 17:06:49
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1377232 | Phd J Michael Williams | One Idexx Drive Westbrook ME 04092 | Executive Vice President | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2015-08-10 | 3,194 | $77.96 | 30,086 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2015-08-10 | 5,000 | $26.66 | 35,086 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2015-08-10 | 2,482 | $17.19 | 37,568 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-08-10 | 6,532 | $77.93 | 31,036 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2015-08-10 | 950 | $77.29 | 30,086 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (Right to buy) | Disposition | 2015-08-10 | 2,482 | $0.00 | 2,482 | $17.19 |
| Common Stock | Non-Qualified Stock Option (Right to buy) | Disposition | 2015-08-10 | 5,000 | $0.00 | 5,000 | $26.66 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-02-13 | No | 4 | M | Direct | |
| 6,586 | 2017-02-13 | No | 4 | M | Direct |
Footnotes
- The number of securities reported reflects a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split") and includes 82 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 6/30/2015.
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $77.75 and $78.03, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,149 shares on 2/14/2010 and 2/14/2013, 4,150 shares on 2/14/2011 and 2/14/2012 and the remaining 1,241 shares on 2/14/2014, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Grant of option to buy shares of IDEXX Laboratories Inc. common stock that became exercisable as to 3,834 shares on 2/14/2011, 2/14/2012, 2/14/2013 and 2/14/2014 and the remaining 1,959 shares on 2/14/2015, without giving effect to the Stock Split. The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
Billionaire Hedge Funds
